Pyxis Oncology, Inc.
PYXS
$1.70
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.86M | 13.86M | 2.82M | 2.82M | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.86M | 13.86M | 2.82M | 2.82M | 0.00 |
| Cost of Revenue | 2.39M | 2.39M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.47M | 11.47M | 2.82M | 2.82M | 0.00 |
| SG&A Expenses | 18.01M | 19.62M | 19.44M | 19.78M | 20.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.03M | 95.70M | 85.45M | 85.73M | 83.16M |
| Operating Income | -83.18M | -81.85M | -82.63M | -82.91M | -83.16M |
| Income Before Tax | -80.35M | -78.24M | -98.97M | -98.17M | -97.40M |
| Income Tax Expenses | 1.39M | 1.39M | -1.88M | -1.88M | -2.16M |
| Earnings from Continuing Operations | -81.74 | -79.62 | -97.09 | -96.29 | -95.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.74M | -79.62M | -97.09M | -96.29M | -95.23M |
| EBIT | -83.18M | -81.85M | -82.63M | -82.91M | -83.16M |
| EBITDA | -78.09M | -77.33M | -80.47M | -80.54M | -80.75M |
| EPS Basic | -1.30 | -1.28 | -1.58 | -1.57 | -1.56 |
| Normalized Basic EPS | -0.80 | -0.79 | -0.79 | -0.79 | -0.78 |
| EPS Diluted | -1.31 | -1.29 | -1.58 | -1.58 | -1.57 |
| Normalized Diluted EPS | -0.80 | -0.79 | -0.79 | -0.79 | -0.78 |
| Average Basic Shares Outstanding | 250.98M | 248.56M | 246.77M | 244.93M | 243.51M |
| Average Diluted Shares Outstanding | 250.98M | 248.56M | 246.77M | 244.93M | 243.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |